METTL14

Summary

METTL14 (methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit, HGNC:29330) is a protein-coding gene on chromosome 4q26, encoding N(6)-adenosine-methyltransferase non-catalytic subunit METTL14 (Q9HCE5). The METTL3-METTL14 heterodimer forms a N6-methyltransferase complex that methylates adenosine residues at the N(6) position of some mRNAs and regulates the circadian clock, differentiation of embryonic stem cells and cortical neurogenesis. It is a selective cancer dependency (DepMap: 78.8% of cell lines).

Enables mRNA binding activity and mRNA m(6)A methyltransferase activity. Involved in mRNA modification; mRNA splicing, via spliceosome; and mRNA stabilization. Located in nucleoplasm. Is active in RNA N6-methyladenosine methyltransferase complex.

Source: NCBI Gene 57721 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 37 total
• Druggable target: yes — 4 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 78.8% of screened cell lines
• MANE Select transcript: NM_020961

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29330
Approved symbol	METTL14
Name	methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit
Location	4q26
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1627
Ensembl gene	ENSG00000145388
Ensembl biotype	protein_coding
OMIM	616504
Entrez	57721

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000388822, ENST00000502564, ENST00000506780, ENST00000508801, ENST00000626212, ENST00000628452, ENST00000900246, ENST00000900247, ENST00000900248, ENST00000900250, ENST00000949682

RefSeq mRNA: 1 — MANE Select: NM_020961 NM_020961

CCDS: CCDS34053

Canonical transcript exons

ENST00000388822 — 11 exons

Exon	Start	End
ENSE00000935079	118691981	118692068
ENSE00001016825	118705611	118705821
ENSE00001016833	118703935	118704051
ENSE00001161537	118691532	118691612
ENSE00001226176	118709998	118715430
ENSE00001504043	118689370	118689457
ENSE00002045472	118685392	118685600
ENSE00003579246	118687923	118688011
ENSE00003637889	118694436	118694526
ENSE00003658931	118700550	118700642
ENSE00003659042	118697182	118697323

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 95.46.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.1406 / max 617.2054, expressed in 1788 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
49425	22.7997	1788
49426	0.3409	126

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	95.46	gold quality
secondary oocyte	CL:0000655	93.03	gold quality
cauda epididymis	UBERON:0004360	91.23	gold quality
islet of Langerhans	UBERON:0000006	91.10	gold quality
caput epididymis	UBERON:0004358	90.50	gold quality
corpus epididymis	UBERON:0004359	90.42	gold quality
ventricular zone	UBERON:0003053	89.54	gold quality
colonic epithelium	UBERON:0000397	89.41	gold quality
tendon	UBERON:0000043	89.27	gold quality
thymus	UBERON:0002370	89.14	gold quality
epithelial cell of pancreas	CL:0000083	89.07	silver quality
right testis	UBERON:0004534	88.82	gold quality
adrenal tissue	UBERON:0018303	88.78	gold quality
left testis	UBERON:0004533	88.66	gold quality
smooth muscle tissue	UBERON:0001135	88.36	gold quality
bone marrow	UBERON:0002371	88.32	gold quality
ganglionic eminence	UBERON:0004023	88.24	gold quality
amniotic fluid	UBERON:0000173	88.00	gold quality
testis	UBERON:0000473	88.00	gold quality
sperm	CL:0000019	87.99	gold quality
trabecular bone tissue	UBERON:0002483	87.86	gold quality
sural nerve	UBERON:0015488	87.73	gold quality
kidney epithelium	UBERON:0004819	87.63	silver quality
cortical plate	UBERON:0005343	87.26	gold quality
nipple	UBERON:0002030	87.15	gold quality
corpus callosum	UBERON:0002336	87.00	gold quality
endothelial cell	CL:0000115	86.93	gold quality
upper arm skin	UBERON:0004263	86.86	silver quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	86.86	gold quality
endometrium	UBERON:0001295	86.69	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.70

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SPI1

miRNA regulators (miRDB)

94 targeting METTL14, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 78.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• methyltransferase-like protein 14 in a complex with METTL3 mediates nuclear RNA methylation (PMID:24316715)
• Structure of the METTL3-METTL14 complex (PMID:27281194)
• The structure reveals the heterodimeric architecture of the complex and donor substrate binding by METTL3. Structure-guided mutagenesis indicates that METTL3 is the catalytic subunit of the complex, whereas METTL14 has a degenerate active site and plays non-catalytic roles in maintaining complex integrity and substrate RNA binding. (PMID:27627798)
• methylation at m6A by METTL3/METTL14 facilitates the methylation of m5C by NSUN2, and vice versa. NSUN2-mediated m5C and METTL3/METTL14-mediated m6A methylation synergistically enhance p21 expression at the translational level (PMID:28247949)
• The critical roles of METTL14 and N(6)-methyladenosine modification in normal and malignant hematopoiesis, are reported. (PMID:29290617)
• METTL3 is soluble and inactive while the catalytic center of METTL14 is degenerated and thus also inactive. In addition, the C-terminal RGG repeats of METTL14 are required for METTL3/14 activity by contributing to RNA substrate binding. (PMID:29348140)
• The Mettl3-Mettl14-mediated m6A was found to promote the development of acute myeloid leukemia and maintain leukemia-initiating cells. (PMID:30006613)
• METTL14 and ALKBH5 determine the N6-methyladenosine of target genes by controlling each other’s expression and by inhibiting YTHDF3.METTL14 role in the cancer growth and progression. (PMID:30306128)
• This demonstrated that EBV hijacks METTL14 to drive EBV-mediated tumorigenesis. METTL14 is now a new target for development of therapeutics for treatment of EBV-associated cancers. (PMID:31226160)
• The N6-methyladenosine mRNA methylase METTL14 promotes renal ischemic reperfusion injury via suppressing YAP1. (PMID:31318098)
• A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity. (PMID:31585521)
• our results demonstrated the functional importance of METTL14-dependent vascular m6A methylome in vascular functions during calcification and provided a novel mechanistic insight to the therapeutic mechanisms of METTL14 (PMID:31697949)
• This work reveals a novel role of Mettl14 and N(6)-methyladenosine in bladder tumorigenesis and bladder TICs, adding new layers for bladder TIC regulation and N(6)-methyladenosine function. (PMID:31760940)
• Bioinformatics analysis demonstrated that downregulated METTL14 mRNA expression has a significantly negative correlation with the kidney renal clear cell carcinoma (KIRC) stages and a positive correlation with overall survival of KIRC patients. Furthermore, circRNAs may regulate METTL14 mRNA as miRNAs sponge to affect the progression of KIRC. (PMID:31976022)
• Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. (PMID:32097728)
• METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. (PMID:32111213)
• METTL14 promotes the migration and invasion of breast cancer cells by modulating N6methyladenosine and hsamiR146a5p expression. (PMID:32323801)
• m6A RNA methylation regulators correlate with malignant progression and have potential predictive values in clear cell renal cell carcinoma. (PMID:32333907)
• METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. (PMID:32552762)
• LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression. (PMID:32576970)
• The study of METTL14, ALKBH5, and YTHDF2 in peripheral blood mononuclear cells from systemic lupus erythematosus. (PMID:32583611)
• METTL14 regulates M6A methylation-modified primary miR-19a to promote cardiovascular endothelial cell proliferation and invasion. (PMID:32633395)
• Lamin A safeguards the m(6) A methylase METTL14 nuclear speckle reservoir to prevent cellular senescence. (PMID:32813328)
• Upregulation of METTL14 mediates the elevation of PERP mRNA N(6) adenosine methylation promoting the growth and metastasis of pancreatic cancer. (PMID:32843065)
• m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. (PMID:32964498)
• Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification. (PMID:33134390)
• Analysis of METTL3 and METTL14 in hepatocellular carcinoma. (PMID:33159022)
• The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway. (PMID:33314339)
• METTL14-regulated PI3K/Akt signaling pathway via PTEN affects HDAC5-mediated epithelial-mesenchymal transition of renal tubular cells in diabetic kidney disease. (PMID:33414476)
• RNA secondary structure dependence in METTL3-METTL14 mRNA methylation is modulated by the N-terminal domain of METTL3. (PMID:33544495)
• Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma. (PMID:33664855)
• CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer. (PMID:33849617)
• USP48 Is Upregulated by Mettl14 to Attenuate Hepatocellular Carcinoma via Regulating SIRT6 Stabilization. (PMID:33903120)
• Methyl CpG binding protein 2 promotes colorectal cancer metastasis by regulating N(6) -methyladenosine methylation through methyltransferase-like 14. (PMID:34097350)
• METTL14 promotes tumorigenesis by regulating lncRNA OIP5-AS1/miR-98/ADAMTS8 signaling in papillary thyroid cancer. (PMID:34131102)
• Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells. (PMID:34332039)
• Human umbilical cord mesenchymal stem cells deliver exogenous miR-26a-5p via exosomes to inhibit nucleus pulposus cell pyroptosis through METTL14/NLRP3. (PMID:34412584)
• METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of alpha-klotho. (PMID:34503454)
• METTL14-Mediated miR-30c-1-3p Maturation Represses the Progression of Lung Cancer via Regulation of MARCKSL1 Expression. (PMID:34586620)
• A methyltransferase-like 14/miR-99a-5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2-mediated epigenetic modulation in esophageal squamous cell carcinoma. (PMID:34586732)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	mettl14	ENSDARG00000070278
mus_musculus	Mettl14	ENSMUSG00000028114
rattus_norvegicus	Mettl14	ENSRNOG00000015250
drosophila_melanogaster	Mettl14	FBGN0032016

Protein

Protein identifiers

N(6)-adenosine-methyltransferase non-catalytic subunit METTL14 — Q9HCE5 (reviewed: Q9HCE5)

Alternative names: Methyltransferase-like protein 14

All UniProt accessions (5): A0A0D9SF88, A0A0D9SFW0, D6RBL4, D6RD73, Q9HCE5

UniProt curated annotations — full annotation on UniProt →

Function. The METTL3-METTL14 heterodimer forms a N6-methyltransferase complex that methylates adenosine residues at the N(6) position of some mRNAs and regulates the circadian clock, differentiation of embryonic stem cells and cortical neurogenesis. In the heterodimer formed with METTL3, METTL14 constitutes the RNA-binding scaffold that recognizes the substrate rather than the catalytic core. N6-methyladenosine (m6A), which takes place at the 5’-[AG]GAC-3’ consensus sites of some mRNAs, plays a role in mRNA stability and processing. M6A acts as a key regulator of mRNA stability by promoting mRNA destabilization and degradation. In embryonic stem cells (ESCs), m6A methylation of mRNAs encoding key naive pluripotency-promoting transcripts results in transcript destabilization. M6A regulates spermatogonial differentiation and meiosis and is essential for male fertility and spermatogenesis. M6A also regulates cortical neurogenesis: m6A methylation of transcripts related to transcription factors, neural stem cells, the cell cycle and neuronal differentiation during brain development promotes their destabilization and decay, promoting differentiation of radial glial cells.

Subunit / interactions. Heterodimer; heterodimerizes with METTL3 to form an antiparallel heterodimer that constitutes an active methyltransferase. Component of the WMM complex, a N6-methyltransferase complex composed of a catalytic subcomplex, named MAC, and of an associated subcomplex, named MACOM. The MAC subcomplex is composed of METTL3 and METTL14. The MACOM subcomplex is composed of WTAP, ZC3H13, CBLL1/HAKAI, VIRMA, and, in some cases of RBM15 (RBM15 or RBM15B).

Subcellular location. Nucleus.

Similarity. Belongs to the MT-A70-like family.

RefSeq proteins (1): NP_066012* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007757	MT-A70-like	Family
IPR029063	SAM-dependent_MTases_sf	Homologous_superfamily
IPR045123	METTL14-like	Family

Pfam: PF05063

Enzyme classification (BRENDA):

• EC 2.1.1.348 — mRNA m6A methyltransferase (BRENDA: 11 organisms, 24 substrates, 64 inhibitors, 6 Km, 5 kcat entries)

Substrate kinetics (BRENDA)

3 substrates with measured Km, best-characterized 3. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ADENINE IN DOUBLE-STRANDED DNA CONTAINING A CYCL	0.0006–0.0007	2
ADENINE IN MRNA	0.0002–0.023	2
ADENINE IN SINGLE-STRANDED DNA	0.0032–0.0077	2

UniProt features (60 total): mutagenesis site 13, helix 12, strand 12, region of interest 9, site 5, turn 4, compositionally biased region 3, chain 1, modified residue 1

Structure

Experimental structures (PDB)

76 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
5IL2	X-RAY DIFFRACTION	1.61
7RX7	X-RAY DIFFRACTION	1.65
5K7M	X-RAY DIFFRACTION	1.65
5K7W	X-RAY DIFFRACTION	1.65
5K7U	X-RAY DIFFRACTION	1.7
5IL1	X-RAY DIFFRACTION	1.71
9RS1	X-RAY DIFFRACTION	1.73
9Q8G	X-RAY DIFFRACTION	1.75
5TEY	X-RAY DIFFRACTION	1.8
7O09	X-RAY DIFFRACTION	1.8
7RX6	X-RAY DIFFRACTION	1.8
7NHI	X-RAY DIFFRACTION	1.85
7RX8	X-RAY DIFFRACTION	1.85
9G4W	X-RAY DIFFRACTION	1.85
9IH5	X-RAY DIFFRACTION	1.85
5L6D	X-RAY DIFFRACTION	1.85
7OEL	X-RAY DIFFRACTION	1.86
5IL0	X-RAY DIFFRACTION	1.88
6Y4G	X-RAY DIFFRACTION	1.9
7O0L	X-RAY DIFFRACTION	1.9
7OEK	X-RAY DIFFRACTION	1.9
5L6E	X-RAY DIFFRACTION	1.9
7NHV	X-RAY DIFFRACTION	1.91
9RRY	X-RAY DIFFRACTION	1.91
9G4S	X-RAY DIFFRACTION	1.95
9Q89	X-RAY DIFFRACTION	1.95
9Q8A	X-RAY DIFFRACTION	1.95
6TTP	X-RAY DIFFRACTION	2
6TTX	X-RAY DIFFRACTION	2
7O08	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCE5-F1	79.88	0.58

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (5): 146 (interaction with mettl3); 242 (interaction with mettl3); 245 (interaction with mettl3); 298 (interaction with mettl3); 399 (interaction with mettl3)

Post-translational modifications (1): 399

Mutagenesis-validated functional residues (13):

Position	Phenotype
63–65	does not affect nuclear localization.
173	little or no effect on s-adenosyl-l-methionine-binding or methyltransferase activity; when associated with a-192.
192	little or no effect on methyltransferase activity. little or no effect on s-adenosyl-l-methionine-binding or methyltrans
198	does not affect methyltransferase activity of the heterodimer complex formed with mettl3.
245	reduced rna-binding. reduced rna-binding; when associated with e-255.
254–255	strongly reduced methyltransferase activity of the heterodimer complex formed with mettl3.
255	reduced rna-binding; when associated with e-245.
297–298	reduced rna-binding.
298	strongly decreased methyltransferase activity of the heterodimer complex formed with mettl3, probably due to reduced rna
312	decreased methyltransferase activity of the heterodimer complex formed with mettl3.
338	does not affect methyltransferase activity of the heterodimer complex formed with mettl3.
362–363	little or no effect on methyltransferase activity of the heterodimer complex formed with mettl3.
399	does not affect interaction with mettl3.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-72203	Processing of Capped Intron-Containing Pre-mRNA
R-HSA-8953854	Metabolism of RNA

MSigDB gene sets: 154 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, LU_IL4_SIGNALING, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_NEUROGENESIS, GOBP_MALE_GAMETE_GENERATION, GOBP_RNA_METHYLATION, GOBP_FOREBRAIN_DEVELOPMENT, GOBP_MRNA_MODIFICATION, GOBP_FOREBRAIN_GENERATION_OF_NEURONS, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, GOBP_REGULATION_OF_LEUKOCYTE_DIFFERENTIATION, GOBP_REGULATION_OF_HEMOPOIESIS

GO Biological Process (16): mRNA splicing, via spliceosome (GO:0000398), RNA methylation (GO:0001510), mRNA processing (GO:0006397), spermatogenesis (GO:0007283), mRNA modification (GO:0016556), stem cell population maintenance (GO:0019827), forebrain radial glial cell differentiation (GO:0021861), response to nutrient levels (GO:0031667), gliogenesis (GO:0042063), regulation of neuron differentiation (GO:0045664), positive regulation of translation (GO:0045727), mRNA stabilization (GO:0048255), mRNA destabilization (GO:0061157), negative regulation of hematopoietic progenitor cell differentiation (GO:1901533), mRNA export from nucleus (GO:0006406), cell differentiation (GO:0030154)

GO Molecular Function (6): mRNA m(6)A methyltransferase activity (GO:0001734), mRNA binding (GO:0003729), RNA binding (GO:0003723), protein binding (GO:0005515), S-adenosylmethionine-dependent methyltransferase activity (GO:0008757), catalytic activity, acting on a nucleic acid (GO:0140640)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), RNA N6-methyladenosine methyltransferase complex (GO:0036396)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA modification	2
mRNA metabolic process	2
regulation of mRNA stability	2
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
macromolecule methylation	1
RNA processing	1
developmental process involved in reproduction	1
male gamete generation	1
multicellular organismal process	1
maintenance of cell number	1
forebrain generation of neurons	1
radial glial cell differentiation	1
response to stimulus	1
neurogenesis	1
neuron differentiation	1
regulation of cell differentiation	1
translation	1
regulation of translation	1
positive regulation of gene expression	1
positive regulation of protein metabolic process	1
RNA stabilization	1
negative regulation of mRNA catabolic process	1
negative regulation of gene expression	1
RNA destabilization	1
positive regulation of mRNA catabolic process	1
hematopoietic progenitor cell differentiation	1
negative regulation of cell differentiation	1
regulation of hematopoietic progenitor cell differentiation	1
RNA export from nucleus	1
gene expression	1
mRNA transport	1
cellular developmental process	1
mRNA methyltransferase activity	1
RNA binding	1
nucleic acid binding	1
binding	1
methyltransferase activity	1
catalytic activity	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

3086 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
METTL14	VIRMA	Q69YN4	999
METTL14	WTAP	Q15007	999
METTL14	ZC3H13	Q5T200	998
METTL14	RBM15	Q96T37	998
METTL14	RBM15B	Q8NDT2	998
METTL14	CBLL1	Q75N03	997
METTL14	METTL16	Q86W50	995
METTL14	METTL3	Q86U44	993
METTL14	METTL4	Q8N3J2	992
METTL14	DGCR8	Q8WYQ5	989
METTL14	SMAD2	Q15796	975
METTL14	ALKBH5	Q6P6C2	952
METTL14	YTHDF1	Q9BYJ9	950
METTL14	YTHDC1	Q96MU7	949
METTL14	YTHDF2	Q9Y5A9	945

IntAct

47 interactions, top by confidence:

A	B	Type	Score
METTL14	METTL3	psi-mi:“MI:0915”(physical association)	0.940
METTL14	METTL3	psi-mi:“MI:0407”(direct interaction)	0.940
METTL3	METTL14	psi-mi:“MI:0407”(direct interaction)	0.940
METTL3	METTL14	psi-mi:“MI:0914”(association)	0.940
METTL3	METTL14	psi-mi:“MI:0407”(direct interaction)	0.780
METTL14	METTL3	psi-mi:“MI:0915”(physical association)	0.780
METTL14	WTAP	psi-mi:“MI:0915”(physical association)	0.580
METTL14	WTAP	psi-mi:“MI:0914”(association)	0.580
WTAP	METTL14	psi-mi:“MI:0915”(physical association)	0.580
METTL3	EIF3H	psi-mi:“MI:0914”(association)	0.560
METTL3	WTAP	psi-mi:“MI:0914”(association)	0.530
METTL14	WTAP	psi-mi:“MI:0914”(association)	0.530
METTL14		psi-mi:“MI:0213”(methylation reaction)	0.440

BioGRID (618): DDI2 (Co-fractionation), METTL3 (Co-fractionation), METTL14 (Affinity Capture-MS), METTL14 (Affinity Capture-MS), METTL14 (Affinity Capture-MS), SMAD2 (Affinity Capture-Western), SMAD3 (Affinity Capture-Western), METTL3 (Affinity Capture-Western), METTL14 (Affinity Capture-Western), METTL14 (Affinity Capture-MS), HSPA8 (Affinity Capture-MS), KRT1 (Affinity Capture-MS), KRT2 (Affinity Capture-MS), HSPA1A (Affinity Capture-MS), KRT10 (Affinity Capture-MS)

ESM2 similar proteins: A2QVS9, A3LS77, A4IFD8, A5E7T4, A8WRG3, A8XYX2, C8V3W5, F4JRS4, F4KAF2, J9VI03, O45380, O60306, O82486, O89042, O94268, P0CO28, P0CO29, P13382, P25583, P32335, P33294, P97496, Q04089, Q2HVD6, Q3UIK4, Q5ADX5, Q5K2C1, Q5K2C4, Q5R5N4, Q5ZK35, Q62847, Q66KJ9, Q6FKD6, Q6FPQ3, Q6FWI7, Q6NU56, Q6NZ22, Q756E1, Q7SB74, Q7YZT6

Diamond homologs: A4IFD8, F1R777, O82486, Q3UIK4, Q5R5N4, Q5ZK35, Q66KJ9, Q6EU10, Q6NU56, Q6NZ22, Q86U44, Q8C3P7, Q94AI4, Q9HCE5, Q9VCE6, Q9VLP7, P41833, Q2HVD6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	27
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2009 predictions. Top by Δscore:

Variant	Effect	Δscore
4:118685597:GCAG:G	donor_gain	1.0000
4:118685600:GGT:G	donor_loss	1.0000
4:118685601:G:C	donor_loss	1.0000
4:118687921:A:AG	acceptor_gain	1.0000
4:118687921:AGTT:A	acceptor_gain	1.0000
4:118687921:AGTTG:A	acceptor_gain	1.0000
4:118687922:G:GG	acceptor_gain	1.0000
4:118687922:GT:G	acceptor_gain	1.0000
4:118687922:GTT:G	acceptor_gain	1.0000
4:118687922:GTTG:G	acceptor_gain	1.0000
4:118687922:GTTGG:G	acceptor_gain	1.0000
4:118688009:CAGGT:C	donor_loss	1.0000
4:118688010:AGG:A	donor_loss	1.0000
4:118688012:G:GC	donor_loss	1.0000
4:118688013:T:A	donor_loss	1.0000
4:118689361:A:AG	acceptor_gain	1.0000
4:118689362:T:G	acceptor_gain	1.0000
4:118689364:TTTCA:T	acceptor_loss	1.0000
4:118689367:CAG:C	acceptor_loss	1.0000
4:118689368:A:AG	acceptor_gain	1.0000
4:118689368:AG:A	acceptor_gain	1.0000
4:118689368:AGG:A	acceptor_gain	1.0000
4:118689369:G:A	acceptor_gain	1.0000
4:118689369:G:GT	acceptor_gain	1.0000
4:118689369:GGG:G	acceptor_gain	1.0000
4:118689369:GGGC:G	acceptor_gain	1.0000
4:118689369:GGGCT:G	acceptor_gain	1.0000
4:118691520:AT:A	acceptor_gain	1.0000
4:118691521:T:G	acceptor_gain	1.0000
4:118691521:T:TA	acceptor_gain	1.0000

AlphaMissense

2992 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:118691604:T:C	F106L	1.000
4:118691605:T:G	F106C	1.000
4:118691606:T:A	F106L	1.000
4:118691606:T:G	F106L	1.000
4:118691608:T:C	L107P	1.000
4:118691981:G:A	G109R	1.000
4:118691981:G:C	G109R	1.000
4:118691982:G:A	G109E	1.000
4:118691990:A:C	S112R	1.000
4:118691992:C:A	S112R	1.000
4:118691992:C:G	S112R	1.000
4:118692002:C:G	H116D	1.000
4:118692005:A:G	N117D	1.000
4:118692007:T:A	N117K	1.000
4:118692007:T:G	N117K	1.000
4:118692008:G:C	D118H	1.000
4:118692008:G:T	D118Y	1.000
4:118692009:A:C	D118A	1.000
4:118692009:A:G	D118G	1.000
4:118692009:A:T	D118V	1.000
4:118692010:T:A	D118E	1.000
4:118692010:T:G	D118E	1.000
4:118692011:T:C	Y119H	1.000
4:118692011:T:G	Y119D	1.000
4:118692014:T:C	C120R	1.000
4:118692015:G:A	C120Y	1.000
4:118692016:C:G	C120W	1.000
4:118692018:A:C	Q121P	1.000
4:118692019:A:C	Q121H	1.000
4:118692019:A:T	Q121H	1.000

dbSNP variants (sampled 300 via entrez): RS1000171053 (4:118686395 G>A), RS10002843 (4:118687821 G>A), RS1000351122 (4:118684947 C>T), RS1000354689 (4:118709549 A>G), RS1000385956 (4:118698908 C>G,T), RS1000535510 (4:118691146 G>A), RS1000559837 (4:118687734 C>T), RS1000726918 (4:118704551 T>G), RS1000779691 (4:118704764 A>C), RS1000909806 (4:118687999 G>A), RS1000959954 (4:118711555 C>T), RS10011169 (4:118702971 A>C,G), RS1001255771 (4:118713844 C>G), RS1001480097 (4:118706756 C>T), RS1001529565 (4:118684493 G>A,T)

Disease associations

OMIM: gene MIM:616504 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4106140 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

4 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 100,849 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL461101	ELTROMBOPAG	4	602
CHEMBL50	QUERCETIN	3	74,559
CHEMBL1214186	SINEFUNGIN	2	2,165
CHEMBL151	LUTEOLIN	2	23,523

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs62328061	METTL14		0.00	0

Binding affinities (BindingDB)

135 measured of 135 human assays (135 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
US20250214997, Compound E-57	IC50	0.1 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
5-[1-[[2-[(4,4-dimethylpiperidin-1-yl)methyl]-1H-indol-6-yl]methyl]triazol-4-yl]-N,N-dimethylpyridin-3-amine	IC50	0.12 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
N-[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methyl]-1-[2-[[4-[5-(3-fluoropyrrolidin-1-yl)-3-pyridinyl]triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine	IC50	0.16 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
N-[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methyl]-1-[2-[[4-(5-pyrrolidin-1-yl-3-pyridinyl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine	IC50	0.16 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-140	IC50	0.17 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-87	IC50	0.19 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-121	IC50	0.2 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-84	IC50	0.24 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-111	IC50	0.24 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-51	IC50	0.25 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-101	IC50	0.25 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-50	IC50	0.29 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-105	IC50	0.29 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-119	IC50	0.29 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenylmethoxyanilino)-6H-pyrido[4,3-d]pyrimidin-5-one;hydrochloride	IC50	0.3 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
N-[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methyl]-1-[2-[[4-(5-pyrrol-1-yl-3-pyridinyl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine	IC50	0.31 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-56	IC50	0.32 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
N-[[6-[[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-5-pyrrolidin-1-ylpyridine-3-carboxamide	IC50	0.33 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
2-[[4-[5-(2,5-dihydropyrrol-1-yl)-3-pyridinyl]triazol-1-yl]methyl]-6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridine	IC50	0.36 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-49	IC50	0.37 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
6-(aziridin-1-yl)-4-[1-[[2-[(4,4-dimethylpiperidin-1-yl)methyl]-1H-indol-6-yl]methyl]triazol-4-yl]-1H-indazole	IC50	0.4 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
6-[(4,4-dimethylpiperidin-1-yl)methyl]-2-[[4-(5-pyrrolidin-1-yl-3-pyridinyl)triazol-1-yl]methyl]imidazo[1,2-a]pyridine	IC50	0.4 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
1-[2-[[4-[5-(3,3-difluoropyrrolidin-1-yl)-3-pyridinyl]triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]-N-[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methyl]methanamine	IC50	0.41 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-106	IC50	0.48 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
6-[[4-[5-(azetidin-1-yl)-3-pyridinyl]triazol-1-yl]methyl]-2-[(4,4-dimethylpiperidin-1-yl)methyl]-1H-indole	IC50	0.5 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-79	IC50	0.54 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
8-bromo-4-(4-phenoxyanilino)-2-[[1-(2,2,2-trifluoroethyl)piperidin-4-yl]amino]-6H-pyrido[4,3-d]pyrimidin-5-one	IC50	0.56 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-59	IC50	0.59 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
8-bromo-4-(3-methyl-4-phenoxyanilino)-2-[(1-methylpiperidin-4-yl)amino]-6H-pyrido[4,3-d]pyrimidin-5-one;hydrochloride	IC50	0.61 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
8-bromo-4-[4-(3,5-difluorophenoxy)anilino]-2-[(1-methylpiperidin-4-yl)amino]-6H-pyrido[4,3-d]pyrimidin-5-one;hydrochloride	IC50	0.69 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
1-cyclobutyl-N-[[2-[[4-[5-(2,5-dihydropyrrol-1-yl)-3-pyridinyl]triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methyl]methanamine	IC50	0.74 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
8-bromo-2-[(1-methylpiperidin-4-yl)amino]-4-(4-phenylmethoxyanilino)-6H-pyrido[4,3-d]pyrimidin-5-one	IC50	0.75 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-39	IC50	0.75 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-143	IC50	0.77 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
8-bromo-4-[3-fluoro-4-(3-fluorophenoxy)anilino]-2-[(1-methylpiperidin-4-yl)amino]-6H-pyrido[4,3-d]pyrimidin-5-one;hydrochloride	IC50	0.8 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
8-chloro-4-(4-cyclohexyloxyanilino)-2-[(1-methylpiperidin-4-yl)amino]-6H-pyrido[4,3-d]pyrimidin-5-one	IC50	0.9 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
1-cyclobutyl-N-[[2-[[4-(5-pyrrolidin-1-yl-3-pyridinyl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methyl]methanamine	IC50	1.02 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
5-[1-[[6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]triazol-4-yl]-N,N-dimethylpyridin-3-amine	IC50	1.06 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
5-(dimethylamino)-N-[[2-[(4,4-dimethylpiperidin-1-yl)methyl]-1H-indol-6-yl]methyl]pyridine-3-carboxamide	IC50	1.09 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
2-[[(3S)-pyrrolidin-3-yl]amino]-4-[4-(trifluoromethyl)anilino]-6H-pyrido[4,3-d]pyrimidin-5-one	IC50	1.17 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-58	IC50	1.18 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
8-bromo-4-[4-(4-chlorophenoxy)anilino]-2-[(1-methylpiperidin-4-yl)amino]-6H-pyrido[4,3-d]pyrimidin-5-one;hydrochloride	IC50	1.21 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
4-[1-[[2-(6-azaspiro[3.4]octan-6-ylmethyl)-1H-indol-6-yl]methyl]triazol-4-yl]-6-methylsulfanyl-1H-indazole	IC50	1.23 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
1-cyclobutyl-N-[[2-[[4-(6-iodo-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methyl]methanamine	IC50	1.24 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-112	IC50	1.25 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
4-[1-[[2-(6-azaspiro[3.4]octan-6-ylmethyl)-1H-indol-6-yl]methyl]triazol-4-yl]-6-bromo-1H-indazole	IC50	1.37 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
8-bromo-4-[4-(4-methylphenoxy)anilino]-2-[(1-methylpiperidin-4-yl)amino]-6H-pyrido[4,3-d]pyrimidin-5-one	IC50	1.38 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-60	IC50	1.39 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
8-bromo-4-[4-(3-fluorophenoxy)-3-methylanilino]-2-[(1-methylpiperidin-4-yl)amino]-6H-pyrido[4,3-d]pyrimidin-5-one;hydrochloride	IC50	1.4 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20250214997, Compound E-43	IC50	1.4 nM	US-20250214997: METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

ChEMBL bioactivities

271 potent at pChembl≥5 of 282 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.00	IC50	1	nM	CHEMBL6171683
9.00	IC50	1	nM	CHEMBL6161197
9.00	IC50	1	nM	CHEMBL6174416
9.00	IC50	1	nM	CHEMBL6162072
8.85	Kd	1.4	nM	CHEMBL5291234
8.70	IC50	2	nM	CHEMBL6149057
8.70	IC50	2	nM	CHEMBL6169196
8.70	IC50	2	nM	CHEMBL6164629
8.70	IC50	2	nM	CHEMBL6145109
8.70	IC50	2	nM	CHEMBL6167143
8.70	IC50	2	nM	CHEMBL6162084
8.70	IC50	2	nM	CHEMBL6170438
8.70	IC50	2	nM	CHEMBL6174400
8.70	IC50	2	nM	CHEMBL6175655
8.70	IC50	2	nM	CHEMBL6173476
8.70	IC50	2	nM	CHEMBL6161072
8.52	IC50	3	nM	CHEMBL6167275
8.52	IC50	3	nM	CHEMBL6169100
8.52	IC50	3	nM	CHEMBL6147720
8.52	IC50	3	nM	CHEMBL6148888
8.52	IC50	3	nM	CHEMBL6163833
8.52	IC50	3	nM	CHEMBL6161072
8.44	IC50	3.63	nM	CHEMBL5396973
8.42	IC50	3.84	nM	CHEMBL5076382
8.41	IC50	3.85	nM	CHEMBL5077332
8.40	IC50	4	nM	CHEMBL6171694
8.40	IC50	4	nM	CHEMBL6143768
8.40	IC50	4	nM	CHEMBL6170155
8.40	IC50	4	nM	CHEMBL6165737
8.40	IC50	4	nM	CHEMBL6165967
8.40	IC50	4	nM	CHEMBL5075067
8.36	IC50	4.35	nM	CHEMBL5405105
8.30	IC50	5	nM	CHEMBL6152127
8.30	IC50	5	nM	CHEMBL6166439
8.30	IC50	5	nM	CHEMBL6161960
8.30	IC50	5	nM	CHEMBL6161072
8.22	IC50	6	nM	CHEMBL6162091
8.22	IC50	6	nM	CHEMBL6147934
8.22	IC50	6	nM	CHEMBL6151936
8.22	IC50	6	nM	CHEMBL6146295
8.22	IC50	6	nM	CHEMBL6161072
8.21	IC50	6.1	nM	CHEMBL5075067
8.21	IC50	6.1	nM	CHEMBL5090558
8.21	IC50	6.1	nM	CHEMBL5094327
8.21	IC50	6.1	nM	CHEMBL5078682
8.21	IC50	6.1	nM	CHEMBL5088632
8.21	IC50	6.1	nM	CHEMBL5082086
8.21	IC50	6.1	nM	CHEMBL5082807
8.21	IC50	6.1	nM	CHEMBL5088101
8.21	IC50	6.1	nM	CHEMBL5084043

PubChem BioAssay actives

67 with measured affinity, of 128 total; 46 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[[6-[(cyclohexylmethylamino)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide	1986901: Binding affinity to full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system assessed as dissociation constant using SAM as substrate by SPR assay	kd	0.0014	uM
1-cyclobutyl-N-[[2-[[4-(6-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methyl]methanamine	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0036	uM
N-[[2-[[4-(6-chloro-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methyl]-1-cyclobutylmethanamine	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0043	uM
(1R,2S,3R,5R)-3-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-[[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methylamino]methyl]-1H-indol-6-yl]cyclopentane-1,2-diol	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0060	uM
N-[(1-methoxycyclobutyl)methyl]-1-[2-[[4-(6-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
N-[[6-[[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methylamino]methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
1-cyclobutyl-N-[[2-[[4-(5-methoxy-1H-indazol-4-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methyl]methanamine	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
N-[[2-[[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methylamino]methyl]-1H-indol-6-yl]methyl]-5-oxo-[1,3]thiazolo[3,2-a]pyrimidine-7-carboxamide	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
N-[[2-[(cyclobutylmethylamino)methyl]-1H-indol-6-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
N-[[2-[(cyclobutylmethylamino)methyl]-5-fluoro-1H-indol-6-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
N-[[2-[[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methylamino]methyl]-1H-indol-6-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
N-[[2-[(3,3-diethylazetidin-1-yl)methyl]-1H-indol-6-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
N-[[2-[[1-(3-fluoro-1-bicyclo[1.1.1]pentanyl)ethylamino]methyl]-1H-indol-6-yl]methyl]-4-oxopyrido[1,2-a]pyrimidine-2-carboxamide	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
N-(1-bicyclo[1.1.1]pentanylmethyl)-1-[2-[[4-(6-methoxyimidazo[1,5-a]pyridin-8-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
1-cyclobutyl-N-[[2-[[4-(6-methoxyimidazo[1,5-a]pyridin-8-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methyl]methanamine	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
N-[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methyl]-1-[2-[[4-(6-methoxyimidazo[1,5-a]pyridin-8-yl)triazol-1-yl]methyl]imidazo[1,2-a]pyridin-6-yl]methanamine	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
(1R,2S,3R,5R)-3-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-(6-azaspiro[3.4]octan-6-ylmethyl)-1H-indol-6-yl]cyclopentane-1,2-diol	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
(1R,2S,3R,5R)-3-(4-amino-5-chloropyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-[[(3-fluoro-1-bicyclo[1.1.1]pentanyl)methylamino]methyl]-1H-indol-6-yl]cyclopentane-1,2-diol	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0061	uM
(1R,2S,3R,5R)-3-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[2-(6-azaspiro[3.4]octan-6-ylmethyl)-1H-indol-6-yl]cyclopentane-1,2-diol	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0062	uM
2-[[4-(6-bromo-1H-indazol-4-yl)triazol-1-yl]methyl]-6-[(4,4-dimethylpiperidin-1-yl)methyl]imidazo[1,2-a]pyridine	1986899: Inhibition of full-length His-tagged METTL3/full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using synthetic RNA 5’P-uacacucgaucuggacuaaagcugcuc-3’ and SAM as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by RF/MS analysis	ic50	0.0079	uM
7-[2-[5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3-pyridinyl]ethyl]-N-methylquinolin-2-amine	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
7-[2-[5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3-pyridinyl]ethyl]-2-ethyl-N-(2-methoxyethyl)-N-methylquinolin-4-amine	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
7-[2-[5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-3-pyridinyl]ethyl]-2-ethyl-N-(2-methoxyethyl)quinolin-4-amine	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
7-[[5-[4-amino-5-[(2S)-oxolan-2-yl]pyrrolo[2,3-d]pyrimidin-7-yl]-3-pyridinyl]methoxy]-N-methylquinolin-2-amine	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
(2R,3R,4S,5R)-5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2-[[2-(azetidin-1-yl)quinolin-7-yl]oxymethyl]-4-fluorooxolan-3-ol	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
(2R,3S,5R)-5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2-[[2-(azetidin-1-yl)quinolin-7-yl]oxymethyl]oxolan-3-ol	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
(2R,3R,4S,5R)-5-(4-amino-5-pyrazol-1-ylpyrrolo[2,3-d]pyrimidin-7-yl)-2-[[2-(azetidin-1-yl)quinolin-7-yl]oxymethyl]-4-fluorooxolan-3-ol	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
(2R,3R,4S,5R)-5-[4-amino-5-(4-methyl-1,3-oxazol-2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2-[[2-(azetidin-1-yl)quinolin-7-yl]oxymethyl]-4-fluorooxolan-3-ol	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
(2R,3R,4S,5R)-5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-2-[[2-(cyclobutylamino)quinolin-7-yl]oxymethyl]-4-fluorooxolan-3-ol	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
(2R,3S,5R)-5-(4-amino-5-pyrazol-1-ylpyrrolo[2,3-d]pyrimidin-7-yl)-2-[[2-(azetidin-1-yl)quinolin-7-yl]oxymethyl]oxolan-3-ol	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
(2R,3R,4S,5R)-5-[4-amino-5-[(2S)-oxolan-2-yl]pyrrolo[2,3-d]pyrimidin-7-yl]-4-fluoro-2-[[2-(methylamino)quinolin-7-yl]oxymethyl]oxolan-3-ol	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
(2S,3R,4S,5R)-5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(azetidin-1-yl)quinolin-7-yl]-4-fluoro-3-hydroxyoxolane-2-carboxamide	1986933: Inhibition of METTL3/METTL14 (unknown origin) using biotinylated RNA (UCUGGACUAAA-biotin) and 3H-SAM as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by scintillation counter analysis	ic50	0.0100	uM
N-[[(3R)-1-[6-(benzylamino)pyrimidin-4-yl]-3-hydroxypiperidin-3-yl]methyl]-4-[(4,4-dimethylpiperidin-1-yl)methyl]-2-hydroxybenzamide	1986898: Inhibition of recombinant METTL3 (354 to 580 residues)/METTL14 (106 to 396 residues) (unknown origin) using m6A oligonucleotide as substrate by HTRF assay	ic50	0.2800	uM
(2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butanoic acid	2119490: Inhibition of METTL3/METTL14 (unknown origin)	ic50	0.5200	uM
(2S,5S)-2,5-diamino-6-[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]hexanoic acid	2119490: Inhibition of METTL3/METTL14 (unknown origin)	ic50	1.3000	uM
Quercetin	2119492: Inhibition of full length His-tagged METTL3 co-expressed with full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using (5’P-UACACUCGAUCUGGACUAAAGCUGCUC-3’) as substrate pre-treated for 60 mins followed by substrate addition and measured for 1 hr by RapidFire mass spectrometry analysis	ic50	2.7000	uM
2-[2-[5-(4-fluorophenyl)-1-(3-phenylphenyl)indol-3-yl]ethoxy]benzoic acid	1986910: Inhibition of METTL3/METTL14 (unknown origin)	ic50	2.7400	uM
2-[2-[1-[4-(2,6-dichlorophenyl)phenyl]-5-(4-fluorophenyl)indol-3-yl]ethoxy]benzoic acid	1986910: Inhibition of METTL3/METTL14 (unknown origin)	ic50	2.8100	uM
2-[2-[5-(4-fluorophenyl)-1-(4-phenylphenyl)indol-3-yl]ethoxy]benzoic acid	1986910: Inhibition of METTL3/METTL14 (unknown origin)	ic50	2.9500	uM
2-[2-[1-[4-(4-chlorophenyl)phenyl]-5-(4-fluorophenyl)indol-3-yl]ethoxy]benzoic acid	1986910: Inhibition of METTL3/METTL14 (unknown origin)	ic50	3.1300	uM
3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid	1986923: Inhibition of METTL3/METTL14 (unknown origin) by bioluminescence assay	ic50	3.6500	uM
5,7,17,19-tetraoxa-13-azoniahexacyclo[11.11.0.02,10.04,8.015,23.016,20]tetracosa-1(13),2,4(8),9,14,16(20),21,23-octaene chloride	2127402: Inhibition of METTL3/METTL14 (unknown origin) by FRET assay	ic50	5.4900	uM
2-[2-[1-benzhydryl-5-(4-fluorophenyl)indol-3-yl]ethoxy]benzoic acid	1986910: Inhibition of METTL3/METTL14 (unknown origin)	ic50	6.0000	uM
2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one	2119492: Inhibition of full length His-tagged METTL3 co-expressed with full length FLAG-tagged METTL14 (unknown origin) expressed in baculovirus expression system using (5’P-UACACUCGAUCUGGACUAAAGCUGCUC-3’) as substrate pre-treated for 60 mins followed by substrate addition and measured for 1 hr by RapidFire mass spectrometry analysis	ic50	6.2000	uM
2-[2-(1-benzhydryl-5-phenylindol-3-yl)ethoxy]benzoic acid	1986910: Inhibition of METTL3/METTL14 (unknown origin)	ic50	8.6300	uM
(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-N-(4-pyrrolidin-1-ylbutyl)oxolane-2-carboxamide	1986897: Competive inhibition of full length human METTL3/METTL14 expressed in Sf9 cells using single strand RNA 5’-AAGAACCGGACUAAGCU-3’ and SAM as substrate incubated for 40 mins by HTRF assay	ic50	8.7000	uM

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, decreases expression, decreases reaction, increases expression	5
Valproic Acid	decreases methylation, decreases expression	2
aristolochic acid I	decreases expression, increases expression	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
deoxynivalenol	increases expression	1
beta-lapachone	decreases expression	1
arsenite	affects binding, increases reaction	1
3-deazaadenosine	decreases reaction, increases expression	1
thallium acetate	decreases reaction, increases expression, affects reaction	1
cupric oxide	increases expression	1
cadmium sulfate	increases expression	1
fumonisin B1	increases expression	1
di-n-butylphosphoric acid	affects expression	1
Docetaxel	increases expression, affects binding, increases reaction, increases methylation, increases response to substance (+2 more)	1
Resveratrol	affects cotreatment, increases expression	1
Decitabine	decreases reaction, decreases response to substance, increases expression, affects binding, increases reaction	1
Arsenic Trioxide	affects binding, increases reaction, decreases reaction, increases phosphorylation, increases expression (+2 more)	1
Acetylcysteine	decreases reaction, increases expression	1
Arsenic	increases expression	1
Benzo(a)pyrene	increases methylation	1
Doxorubicin	increases expression, increases abundance, increases reaction, increases methylation, increases stability (+1 more)	1
Ethyl Methanesulfonate	increases expression	1
Ivermectin	decreases expression	1
Lipid Peroxides	increases abundance, increases reaction	1
Lipopolysaccharides	affects reaction, increases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1

ChEMBL screening assays

45 unique, capped per target: 45 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4005637	Binding	Inhibition of METTL3-14 (unknown origin) at 10 uM using biotin-labeled peptide as substrate and [3H]-SAM measured after 1 hr by scintillation proximity assay	Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SX93	HAP1 METTL14 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.